Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game - Starter Deck 03 ‘Ω to the Future’ and Booster Pack 04 ‘Gleam of Eternal Hope’, launching globally on Friday, 25 July 2025 and Friday, 1 August 2025 respectively. These upcoming game sets build on the momentum of the newly launched Ultraman Omega television series, as well as beloved characters such as Ultraman Arc, whilst introducing brand-new gameplay mechanics, evolution strategies and dynamic synergies centred around these iconic Ultra Heroes. Ultraman Omega Makes His First-Ever Card Game AppearanceA highlight of the new Starter Deck 03 ‘Ω to the Future’ is the much-anticipated debut of Ultraman Omega in card form. This new deck draws inspiration from the ongoing Ultraman Omega television series, which premiered in Japan earlier this month.Reflecting the show’s narrative, the deck features exclusive cards from the Ultraman Omega series, including the titular Ultraman Omega, Meteokaiju, and fan-favourite Giants of Light such as Ultraman Arc. These new cards introduce fresh gameplay mechanics that reward strategic thinking and foresight, from granting power boosts when fielding characters of the same type to enabling tactical card rotations that encourage smarter deck management. With these new mechanics and play styles, players can look forward to reliving key story moments and experiencing Ultraman Omega’s growth firsthand.As an added early-release bonus, players will also be able to receive a bonus pack of Booster Pack 04 ‘Gleam of Eternal Hope’ for every purchase of Starter Deck 03 ‘Ω to the Future’, offering fans an early taste of the upcoming expansion and even more ways to power up their decks.Fan-Favourite Heroes Return with Upgraded PowersBooster Pack 04 ‘Gleam of Eternal Hope’ continues to expand the strategic possibilities of the game, featuring powerful upgraded cards for popular Ultra Heroes including Ultraman Dyna, Ultraman Z, and Ultraman Trigger.These upgrades introduce new abilities that not only refresh existing decks but also deepen tactical options across competitive formats. With a more extensive card pool, players can look forward to more creative deckbuilding strategies that are sure to influence the current approach to gameplay.Collectors Rejoice: ExP (Extra Parallel) Cards Make a ReturnBack by popular demand, the ExP (Extra Parallel) rarity cards - first introduced in Booster Pack 02 ‘Vortex of Crimson and Azure’ - make a dazzling return in ‘Gleam of Eternal Hope’.These collector-favourite cards are known for their exclusive full-art illustrations, premium foil finish, and elegant gold framing. Scheduled to be revealed on Friday, 1 August 2025, ‘Gleam of Eternal Hope’ will see the addition of two brand-new types of ExP card, offering high visual appeal and collectability for long-time fans and new enthusiasts alike.Exclusive Box Topper: Alien Baltan The Space NinjaAdding to the excitement, each 24-pack box of ‘Gleam of Eternal Hope’ will include a special box topper card featuring Alien Baltan, one of the most iconic villains in Ultraman history.This unique card mirrors Baltan’s illusory powers, allowing an unlimited number of copies to be included in a single deck - a rare and rule-breaking mechanic. The artwork captures the classic scene of Baltan duplicating itself and unleashing its signature red freezing ray, leveraging nostalgia for long-term fans.Fans in Malaysia can look forward to purchasing the English-language Starter Deck 03 ‘Ω to the Future’ at MYR 46.00 and Booster Pack 04 ‘Gleam of Eternal Hope’ in either individual packs at MYR 18.00 or as a 24-pack box at MYR 432.00 at authorised hobby stores, major retailers, and online platforms.These releases are poised to equip both new and veteran Ultra Leaguers with competitive decks ahead of major events, including the upcoming inaugural Ultra League World Championship 2026, set to take place on 9 and 10 May 2026 in Tokyo, Japan. This prestigious tournament will see players from around the world battling through regional qualifiers for a shot at the title of world’s best Ultra Leaguer, with exclusive cards and gameplay accessories up for grabs. For more information on the Ultraman Card Game, please refer to https://ultraman-cardgame.com/page/my/top.About Tsuburaya ProductionsTsuburaya Productions is a global entertainment company providing content, products and services full of creativity and innovation. Since the airing of Ultra Q and Ultraman in 1966, the company has continued to create characters and stories that are loved by fans worldwide.TSUBURAYA PRODUCTIONS Official Global Site: https://tsuburaya-prod.com/Ultraman Card Game Official Website: https://ultraman-cardgame.com/About Ultraman Card Game​The Ultraman Card Game is a dynamic trading card game developed by Tsuburaya Productions, bringing the iconic Ultraman universe to life through strategic gameplay and collectible cards. Designed for fans of all ages, the game features high-quality artwork showcasing Ultraman's heroes, kaiju, and special moves, offering both engaging play and collectibility. With simultaneous releases in multiple languages across various regions, the Ultraman Card Game invites players around the world to explore the rich legacy of Ultraman, engage in epic battles, and grow their collections. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that (Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC.The Approved Product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5ml:150mg), indicated for the treatment of dry eye syndromes such as conjunctival epithelium injury and tear abnormalities. The active pharmaceutical ingredient, diquafosol sodium, is a P2Y2 receptor agonist that acts on conjunctival tissues to promote the secretion of tears containing water and secretory mucins. It may also promote the expression of membrane-bound mucins on corneal epithelium. Boosting the lipid content in tears, it should quantitatively and qualitatively improve tear abnormalities and demonstrate efficacy in bringing the ocular surface condition closer to normal, and improve symptoms of dry eye and corneal epithelial damage.The Approved Product, together with the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops collectively, collectively provide more high-quality treatment options for patients in the PRC.  The approval will further enrich the Group’s ophthalmic product portfolio and strengthen its market position in ophthalmology segment.About Essex (Stock Code:1061.HK)Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a discount of approximately 4.98% to the average closing price of HK$73.35 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Date.- a premium of 16.15% to the volume weighted average price of HK$60.01 per Share as quoted on the Stock Exchange for the thirty consecutive trading days immediately prior to the Last Trading Date and including the Last Trading Date.The gross proceeds from the Placing and Subscription are expected to be approximately HK$1,572.50 million, and the net proceeds (after deducting all related expenses, including commission and levies) will be approximately HK$1,553.39 million.Everest Medicines intends to use approximately 50% of the net proceeds (approximately HK$776.69 million) to support global research and development of pipeline products, approximately 40% (approximately HK$621.36 million) to commercialization efforts including the launch of new products, and 10% (approximately HK$155.34 million) to working capital and general corporate purposes.“This placement was well-received by several leading international long-only funds and was significantly oversubscribed, reflecting strong capital market confidence in Everest’s commercial execution capabilities and innovative R&D strengths,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “It also underscores investors’ endorsement of our long-term strategic vision. We will use the proceeds to accelerate the development of innovative pipelines and our proprietary AI+mRNA platform, while advancing the commercialization of our existing portfolio. With a strengthened capital base, we are poised to drive both commercialization and innovation, delivering greater value to patients and shareholders.”Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform, enabling the development of multiple oncology and autoimmune disease programs, including EVM14, an off-the-shelf therapeutic mRNA cancer vaccine; EVM16, a personalized mRNA cancer vaccine; and an in vivo CAR-T program aimed at building a differentiated portfolio of precision immunotherapies.- The first patient has been dosed with Everest’s internally developed personalized mRNA cancer vaccine (PCV) EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT). Early results showed strong immunogenicity and specific T-cell responses even at a low starting dose in advanced cancer patients.- The Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine, has been accepted by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), making it Everest's first mRNA cancer therapeutic vaccine to achieve dual IND submissions in both China and the United States. The first clinical batch of EVM14 was successfully released from Everest’s Jiashan manufacturing site on June 9, and is anticipated to be delivered to U.S. clinical centers by mid-August. This batch will support the clinical trials of EVM14 in both China and the United States (US).- Everest’s in vivo CAR-T program is founded upon its proprietary targeted LNP (tLNP) delivery system and has shown promising results in both humanized mouse models and non-human primates. It offers key advantages including off-the-shelf availability, lymphodepletion-free administration, and dose controllability.EVER001, a next-generation covalent reversible BTK inhibitor with global rights, is advancing through global multi-center clinical studies for glomerular diseases such as primary membranous nephropathy (pMN). Positive results from its Phase 1b/2a clinical trial demonstrated rapid onset, durable response, good tolerability, and oral convenience, offering strong potential to address unmet needs in renal disease treatment worldwide.NEFECON®, the first and only etiological treatment for IgA nephropathy (IgAN) full approved in China, the U.S., and Europe, continues to gain strong commercial traction in China following its inclusion in the National Reimbursement Drug List (NRDL), benefiting over 20,000 patients to date. Everest is also accelerating the development of its proprietary diagnostic test for Gd-IgA1 to build an integrated disease management ecosystem encompassing diagnosis, treatment, and long-term care.The New Drug Application (NDA) for Etrasimod (VELSIPITY®) has been accepted in Mainland China, with approval anticipated between late 2025 and early 2026. The NDA has also been accepted in South Korea. VELSIPITY® has been commercially launched in Macao SAR, Singapore and Hong Kong SAR in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. In March 2025, Everest has launched the construction project at its Jiashan manufacturing site to support the local production for VELSIPITY®.Everest Medicines is accelerating the strategic advancement of its core pipeline and AI+mRNA technology platforms to further solidify its position as a leading innovative biopharmaceutical company in Asia.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 亿胜生物科技有限公司（"亿胜生物"或"集团"，股票代码：1061.HK）欣然宣布，集团间接全资附属公司珠海亿胜生物制药有限公司已收到国家药品监督管理局批准于中华人民共和国进行多剂量地夸磷索钠滴眼液（"获批准产品"）注册及商业化。获批准产品是一款含有3%地夸磷索钠（5ml:150mg）的多剂量滴眼液剂型，适用于包括结膜上皮损伤和泪液异常在内的干眼症的治疗。该活性药物成分地夸磷索钠是一种P2Y2受体激动剂，它作用于结膜组织，促进含有水分和分泌性粘蛋白的泪液分泌。它还可促进角膜上皮上膜结合型粘蛋白的表达。通过提升泪液中的脂质含量，它从数量和质量上改善泪液异常，并显示出使眼表状况接近正常、改善干眼症状和角膜上皮损伤的疗效。获批准产品将与集团已获批的不含防腐剂单剂量地夸磷索钠滴眼液一并，为不同类型的中国患者提供更多优质治疗选择。此地夸磷索钠滴眼液的成功获批将进一步丰富集团眼科产品组合，增强集团在眼科领域的市场地位。关于亿胜生物（股票代码﹕1061.HK）亿胜生物是一间专注于研发、生产和销售基因工程药物b-bFGF的生物制药企业，拥有包括贝复舒®、贝复济®、贝复新®在内的六种基因工程药物在中国上市销售。此外，公司还拥有包含一系列不含防腐剂单剂量滴眼液和适丽顺®卵磷脂络合碘胶囊等的多元化产品组合，主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗。这些产品在公司于中国的44个区域办事处的支持下，在逾14,000家医院进行营销和销售。依托自身在生长因子和抗体技术领域的研发平台，亿胜生物在多个临床阶段拥有强大的项目管线，涵盖广泛的领域和适应症。 Copyright 2025 亚太商讯 via SeaPRwire.com.

上海，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀有限公司（HKEX1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布以先旧后新配售22,561,000股，集资约15.725亿港元，发行股份数占现有股本约6.87%, 占经扩大后的总股数约6.43%。云顶新耀、卖方（控股股东康桥资本）与配售代理签订先旧后新方式的配股协议，配售22,561,000股份，每股配售价69.70港元，较于最后交易日（即配售及认购协议日期前一天）在联交所报所报收市价每股77.55港元折让约10.12%，亦较于紧接最后交易日（包括该日）前连续五个交易日在联交所所报平均收市价每股73.35港元折让约4.98%，较于紧接最后交易日（包括该日）前连续三十个交易日在联交所所报成交量加权平均价每股60.01港元溢价16.15 %。所得款项总额预期约为15.725亿港元，而所得款项净额（经扣除所有相关成本及开支，包括佣金及征费）将约为15.534亿港元。云顶新耀预计配售所得款项，其中50 %（约7.767亿港元）用于开发自主全球研发平台及新产品管线；另外40 %（约6.214亿港元）用于推进新产品商业化，包括推出新产品；及10 %（约1.553亿港元）用作营业资金以及一般及行政用途。云顶新耀首席执行官罗永庆表示，"此次配售受到多家国际长线持有基金青睐，获得数倍超额认购，反映了资本市场对云顶新耀商业化能力与创新研发实力的高度认可，也体现出投资者对公司长期发展战略的充分信心。我们将充分利用此次融资所得，加快创新药物和AI+mRNA平台的开发，同时推进现有产品的商业化进程。凭借更为充足的资本基础，我们有信心在商业化拓展与研发创新双线并进，不断为患者与投资者创造更大价值。"公司已构建国际领先的、完全整合且本地化的AI+mRNA平台，重点推进肿瘤和自身免疫疾病领域的产品管线开发，包括通用型现货肿瘤治疗性疫苗EVM14、个体化肿瘤治疗性疫苗EVM16，以及自体生成CAR-T项目。- 云顶新耀自主研发的首款个性化mRNA治疗性肿瘤疫苗EVM16 的IIT研究已在今年3月于北京大学肿瘤医院顺利完成首例患者给药。该临床试验初步数据显示，即使低起始剂量也能激发晚期肿瘤患者特异性T细胞反应，具有良好的免疫原性。- 通用型现货肿瘤治疗性疫苗EVM14注射液的新药临床试验申请（IND）已获中国国家药品监督管理局和美国食品药品监督管理局（FDA）受理，成为公司首个实现"中美双报"的mRNA肿瘤治疗性疫苗。云顶新耀嘉善工厂已于2025年6月9日顺利放行首批GMP临床试验样品，该批样品将用于支持云顶新耀在中美两地开展EVM14的临床试验。- 自体生成CAR-T项目也已在人源化小鼠与非人灵长类（猴）模型中验证有效，具备现货型、无需淋巴耗竭、剂量可控等优势，展现了开发用于肿瘤及自身免疫疾病的潜力。拥有全球权益的新一代共价可逆BTK抑制剂EVER001正开展全球多中心临床研究，主要用于治疗原发性膜性肾病（pMN）等多种原发性肾小球疾病。其在原发性膜性肾病1b/2a期研究中展现出起效快、缓解持续、耐受性好、口服便捷等综合优势，有望为全球患者带来更优治疗选择。耐赋康®作为首个且唯一在中国、美国和欧洲获得完全批准的IgA肾病对因治疗药物，自纳入中国国家医保目录以来快速放量，已惠及超过两万名患者。公司亦正加快推进Gd-IgA1诊断试剂的转化，致力打造覆盖诊断、治疗、长期管理的一体化IgA肾病疾病管理生态。伊曲莫德（维适平®）在中国大陆的新药上市申请也已获受理，预计2025年底至2026年初获批，其新药上市申请也已获韩国受理。伊曲莫德已相继在中国澳门，新加坡和中国香港获批，并被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（2024年），已在大湾区先行使用惠及溃疡性结肠炎患者，成为云顶新耀第三款商业化新药。2025年3月，云顶新耀启动了伊曲莫德位于嘉善工厂的生产建设项目，为伊曲莫德的本地化生产提供支持。云顶新耀正加快推进多个核心管线及技术平台的战略布局，进一步巩固其在亚洲领先创新药企中的市场地位。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站：www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 随着粤港澳大湾区建设不断深化，区域内居民对跨境医疗服务与医疗保险协同发展的需求日益迫切。7月24日，一场以"粤港澳大湾区医疗保险发展"为主题的行业论坛于香港举行，来自保险、医疗、科技等领域的机构代表与专家齐聚一堂，围绕跨境医疗保障一体化、保险产品创新与服务标准化等核心议题展开深入交流。论坛期间，各方共同探讨大湾区医疗保险发展新路径，并见证跨境医疗行业解决方案正式发布。聚焦医疗互联互通，发布跨境保障方案论坛上，镁信健康创始人兼首席执行官张小栋先生指出，粤港澳大湾区作为我国经济最具活力的区域之一，在国家发展大局中具有重要战略地位。"塑造健康湾区"战略的践行，是对千万湾区居民"病有所医、医有所保"期盼的回应。镁信健康围绕"药品可及、医疗连接、支付简化"三个核心痛点，推出跨境医疗解决方案，具体涵盖：第一件事，是"把药带进来"。依托镁信创新药械的资源优势，致力于把最新上市的癌症、罕见病治疗药、以及海南特药特械等全球创新药械带到大湾区患者的身边；第二件事，是"把医连起来"。提供包括专家预约、陪诊、第二诊疗意见、住院手术安排等全流程服务，优化港人北上诊疗体验；第三件事，是"把支付变简单"。依托镁信的一码直付平台，探索实现患者北上就医无需垫付，努力让跨境医疗的保险理赔像扫码一样简单。镁信健康创始人兼首席执行官 张小栋在跨境医疗解决方案环节，中再寿险产品开发部总经理王明彦先生与镁信健康首席商务官郎立良先生也分别发表主题演讲。他们深入探讨了跨境医疗在大湾区面临的机遇与挑战，分享了在产品设计、服务模式等方面的创新实践与经验。汇聚行业智慧 共建健康湾区活动现场同步举行「服务国家战略，共建健康湾区」发布仪式，宣布各方将在资源整合，模式创新等层面持续合作，探索更多适配于大湾区的医疗保险产品与服务。在随后的圆桌论坛环节，由镁信健康首席商务官郎立良先生担任主持人，与尚志医疗集团医务行政总监、外科专科医生郭宝贤先生，中国太平洋人寿（香港）联席行政总裁、香港精算学会（ASHK）前主席、现任理事Simon Lam先生，香港精算视觉保险学会会长、大湾区保险学院联合创始人牟剑群先生，以及诺华香港的相关代表深入探讨大湾区医疗保融合的各方实践。各位嘉宾从不同角度分享了对大湾区医疗保险发展的见解与建议，探讨了如何加强大湾区医疗保障合作、提升医疗服务水平、促进保险产品创新等关键问题。镁信健康在论坛中积极发声，提出通过公立+特需/私立结合、资源整合等方式，赋能医疗资源的互补和互通，推动大湾区医疗保险服务的升级与优化，为大湾区居民提供更加优质的医疗保障体验，得到了与会嘉宾的广泛认可与支持。「服务国家战略，共建健康湾区」发布仪式凝聚信心 携手同行论坛压轴环节，中国太平洋人寿保险原董事长、大家保险集团原总经理徐敬惠先生发表主旨发言。他从行业发展的宏观角度，对大湾区医疗保险的未来发展进行了深入分析与展望，总结出三个"心"的感受。首先是信心，近年来，在各项政策的推动下，大湾区医疗互联互通成效明显，多项跨境医疗福利成功"过河"，跨境医疗的"民生流量"也在政策协同的推动下持续升温，这让我们对未来充满信心。第二个是"初心"，徐敬惠先生强调，"以人民健康为中心"的初心，是破解难题的指南针。最后是"同心"，不管是中再、镁信，还是医疗、医药机构，都在各自领域搭建着连通桥，各方携手共同推动大湾区医疗保险事业的发展，为大湾区居民的健康保驾护航。此次论坛发布的"湾区跨境医疗解决方案"，镁信健康深度参与并提供特药支持。它打破了地域壁垒，整合了两地资源，为跨境医疗服务的标准化、一体化树立了典范。这种合作模式不仅提升了居民的健康保障体验，也为行业探索出了一条可持续发展的新路。本次粤港澳大湾区医疗保险发展论坛的顺利举行，不仅推动了湾区保险行业对跨境医疗议题的深度关注，也为后续创新与产业协作奠定了良好基础。镁信健康作爲参与方之一，将持续深耕大湾区，携手更多伙伴推进医疗保障数智化转型，助力实现健康湾区的美好愿景。 Copyright 2025 亚太商讯 via SeaPRwire.com.

DUBAI, July 21, 2025 - (ACN Newswire via SeaPRwire.com) - 31 Concept (31C), a technology startup specializing in advanced network intelligence and traffic visibility solutions, today officially announces its emergence from stealth mode. Following a successful $6 million pre-seed funding round in December 2024, the company has grown to a team of 35 world-class professionals and quietly achieved several critical milestones, including the development of its flagship platform designed to enhance digital sovereignty, cyber defense, and national infrastructure visibility.31 Concept Next-Gen Network IntelligenceOver the past several months, 31C has operated in stealth while building a groundbreaking platform that enables real-time inspection and classification of network traffic - even when encrypted. This advanced solution is engineered to help governments, regulators, law enforcement agencies, and large enterprises gain deep visibility into digital communications and infrastructure activity. It combines high-performance packet-level analytics with AI-driven intelligence.At the ISS Asia 2025 Conference, taking place the first week of September in Singapore, 31 Concept will publicly debut its platform for the first time in a closed-door session dedicated to government, regulatory, and law enforcement audiences. This presentation will include a live demonstration, showcasing how 31C's technology provides deep, actionable insights critical for national and digital security."We've spent the past year building in silence, and now we're ready to show the world what we've been working on," said Misha Hanin, CEO of 31 Concept. "Our mission is to enable the guardians of digital infrastructure to reclaim visibility and control-especially in a world dominated by encryption, fragmentation, and geopolitical uncertainty."The $6 million in initial funding (Pre-seed) came from a mature strategic investor who shared the company's vision and long-term approach to innovation. Since then, 31C has successfully delivered multiple technical and business milestones, validating the platform's real-world applicability.Pioneering Research Through 31C Research DivisionAt the core of 31C's long-term innovation strategy lies its dedicated research division - 31C Research. This division operates at the intersection of science and technology, bringing together a global team of PhDs in quantum cryptography, professors in mathematics, and hands-on experts in cybersecurity, networking, and artificial intelligence.Unlike traditional R&D teams, 31C Research isn't just focused on product development; it is tasked with pushing the boundaries of what's possible in intelligent traffic analysis, encrypted data interpretation, and quantum-resistant security frameworks. The division is already contributing to advanced studies in post-quantum cryptography, secure communications, and AI-augmented traffic inspection.In line with the company's commitment to give back to the global tech community, 31C Research will also begin open-sourcing selected internal tools and research assets on GitHub, supporting collaboration, transparency, and educational initiatives across the cybersecurity ecosystem."Our research arm reflects our belief that fundamental breakthroughs come when rigorous science meets real-world urgency," said Boriss Heismann, CTO of 31C. "We're not just building for now-we're building for the next era of cybersecurity and digital defense."Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 Concept Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - International Land Alliance, Inc. (OTCQB: ILAL) (“ILAL” or the “Company”), a global real estate investment and development firm, today announced the launch of a new product offering at its flagship Cabo Oasis and Valle Divino developments in Baja California. With a focus on sustainable design and affordability, this initiative marks a significant expansion of the Company’s master-planned communities.International Land Alliance has identified initial locations within its 500-acre Cabo Oasis beachfront development to introduce Tesla-powered tiny homes. These units are designed to serve as vacation, second, or retirement residences—offered at a purchase price of under $100,000 or a lease option for under $1,000 per month.“We are bringing sustainable, high-quality living to everyone at a price that was once unimaginable,” said Frank Ingrande, President & CEO. “These homes emphasize eco-friendly design, compact efficiency, and cutting-edge technology, all while helping solve the affordability crisis that’s impacting many, especially in California.”As part of our broader vision to expand Cabo Oasis, ILAL is developing separate private neighborhoods within the master-planned community to accommodate a wide variety of homeownership needs and budgets—including condominiums, private estates, and these new tiny home options.The Company is currently in discussions with a leading tiny home manufacturer and expects to receive its first Tesla-powered model at Cabo Oasis within the next 30 days. The name of the provider will be announced shortly thereafter.The tiny homes will be available in both stationary and mobile versions, enabling owners to relocate between ILAL’s growing portfolio of communities across Baja California.Key Features of the Cabo Oasis Tiny Homes:Solar-Powered Everything – Integrated Tesla Solar Roof panels and a Powerwall battery ensure energy independence making this 100% off-grid capable.Smart Home Integration – Includes full home automation for lighting, climate, and security controls.Sleek, Futuristic Design – Modular interiors that maximize space and feature premium finishes.Zero Utility Costs – Energy-efficient systems designed to eliminate traditional energy bills.About Cabo OasisCabo Oasis is International Land Alliance’s flagship beachfront community in Baja California, featuring 500 acres of master-planned development with ocean views, resort amenities, and a wide range of residential options designed for sustainable coastal living.About Valle DivinoLocated in the heart of Baja’s wine country, Valle Divino is a luxury vineyard community that offers scenic living amidst Ensenada’s world-renowned wine region. The project blends boutique vineyard living with modern sustainability.About International Land Alliance, Inc.International Land Alliance, Inc. (OTCQB: ILAL) is a publicly traded real estate development company focused on acquiring desirable land and real estate assets in Northern Baja California and Southern California. With a mission to provide accessible housing solutions through innovative design and technology, ILAL builds environmentally friendly communities for vacation, retirement, and investment buyers.International Land Alliance, Inc. (OTCQB: ILAL) is an international land investment and development firm based in San Diego, California. As its’ core mission, the Company has embraced technology for sustainable and socially responsible solutions, in addition to using proptech and construction tech advanced applications to meet these goals. The Company is focused on acquiring attractive raw land primarily in Northern Baja California, often within driving distance from Southern California. The Company serves its shareholders by devoting considerable time and resources to seeking out the finest sites available and obtaining the necessary development permits to build a compelling portfolio of properties, which provide a diversity of investment and living options. Please visit: www.ila.company.For media inquiries, contact:Investor Relationsinfo@ila.company(877) 661-4811www.ila.company Safe Harbor StatementThe press release may include certain statements that are not descriptions of historical facts but are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking terminology such as "may," "expects," "believes," "anticipates," "intends," "projects,” or similar terms, variations of such terms or the negative of such terms. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All such assumptions are inherently subject to significant economic and competitive uncertainties and contingencies beyond our control and upon assumptions with respect to the future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectations and actual results may vary (perhaps materially) from certain of the results anticipated herein. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The implementation of streamlined approval procedures for Hong Kong- and Macao-registered proprietary Chinese medicines (“pCms”) by mainland China presents significant opportunities for Hong Kong companies to expand into the Greater Bay Area and other mainland market.- A unified and comprehensive registration system strengthens the quality control of Hong Kong's pCms, reinforcing confidence among other regulatory bodies and stakeholders.- Hong Kong's first Chinese medicine hospital will gradually commence operations by year end. This will help promote the popularity of Chinese medicine and pCms.HONG KONG, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (“HKTDC”) today released a report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry," that analyses the sector’s development, challenges, and export potential of Hong Kong’s pCm sector. With the completion of the transitional registration process for pCms in June this year, all pCms sold in Hong Kong now hold formal registration, marking a new era in the regulatory regime. The Chinese Medicine Hospital of Hong Kong is set to begin operations by late 2025 further popularising pCms. Additionally, mainland China has streamlined approval procedures for Hong Kong-registered traditional pCms, creating easier access to the mainland market.Hong Kong’s pCms enjoy a strong reputation, with streamlined registration procedures facilitating expansion into the Mainland marketHong Kong currently has approximately 2,000 companies involved in pCms and Chinese herbal medicine-related businesses, including import/export trade, manufacturing, wholesale and retail. Among these, some 264 enterprises are listed as local pCm manufacturers. The majority of pCms produced in Hong Kong are geared toward the consumer market. In 2024, Hong Kong’s pCm exports totaled HK$2.88 billion with 93% locally produced, setting the industry apart from re-export-driven sectors. Mainland China remains the largest export market, accounting for over 70% of exports, followed by Macao (20%), and ASEAN (6%).Wing Chu, Principal Economist (Greater China) of the HKTDC, stated: "Many Hong Kong proprietary Chinese medicines companies are eager to expand exports especially to the mainland market although pCm imports in mainland China are relatively small, with different pCms registration system and technical standards from those of Hong Kong. Notably, Hong Kong’s pCms are highly regarded in Southern China and overseas Chinese communities, and streamlined approval procedures in mainland China for traditional pCms of Hong Kong and Macao offer significant opportunities for Hong Kong businesses to expand into the Greater Bay Area and other mainland markets. Additionally, the rise of online shopping enables companies to leverage cross-border e-commerce platforms to access mainland and overseas markets, provided they comply with the corresponding regulatory requirements.”Comprehensive registration system drives standardisation of Chinese medicineThe report indicates that, in recent years, the HKSAR Government has actively promoted the development of Chinese medicine. Key initiatives include the establishment of the Chinese Medicine Council of Hong Kong to oversee the registration and management of pCms, and continuous support for Chinese medicine services in areas such as education, medical treatment, and scientific research. These efforts have enabled Hong Kong to cultivate professional Chinese medicine talent and promote the modernisation of Chinese medicine. Earlier this month, some 345 Hong Kong enterprises, including traders, registered a total of 8,244 pCms.The report states that a unified and comprehensive registration system enhances the quality control of Hong Kong's pCms, further increasing the confidence of other regulatory bodies and stakeholders in these products. Hong Kong's first Chinese medicine hospital is set to open in late 2025, providing comprehensive diagnostic and treatment services with Chinese medicine, which will drive the popularisation of Chinese medicine and pCms.In addition, Hong Kong pCm companies and local universities are committed to developing new pCms to further expand the market. Recently, the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist University (HKBU), funded by the Innovation and Technology Commission of HKSAR Government under the InnoHK Research Clusters, developed a novel drug, CDD-2101, for the treatment of chronic constipation. The innovation is based on previous pilot clinical studies and basic research on the traditional Chinese herbal formulation "MaZiRenWan”. For the first time, it has received authorisation for clinical research in the United States.Prof. BIAN Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development and Associate Vice-President (Clinical Chinese Medicine) at HKBU, said: "Our goal is to collect sufficient safety and efficacy data to obtain FDA approval for CDD-2101 as a marketable new drug and successfully launch it in the United States. This represents not only a major breakthrough in the research and development of Chinese medicine in Hong Kong but also an important step in driving the standardisation and internationalisation of Chinese medicine.”Mainland market surpasses RMB450 billionMainland China, the world's largest pCm market valued at RMB450 billion, streamlined registration and approval procedures in 2021 for traditional pCms for external use being sold in Hong Kong and Macao. In January 2025, the National Medical Products Administration further simplified the approval process for traditional pCms for oral use, provided they have been in use in Hong Kong for more than 15 years and whose production processes comply with Good Manufacturing Practice (GMP) requirements. Relevant application materials and technical requirements were also released in April this year. The report notes that the implementation of the streamlined registration procedures opens a more convenient channel for Hong Kong companies to expand into the Greater Bay Area and other mainland markets.The recognition and acceptance of pCms differ across overseas regions. In many international markets, pCms are categorised and regulated as herbal medicines, health foods or dietary supplements. However, many Southeast Asian countries have specific, similar legal requirements for pCms, providing a clear pathway to enter these markets.The rapid growth of global e-commerce has created new sales channels for Hong Kong’s pCms through cross-border e-retail. For the mainland market, the report points out that certain pCms for external use, such as Chinese medicinal wines and cooling oils, have been incorporated in the Cross-border E-commerce Retail Import Commodity List, allowing relevant products to be sold to mainland China through cross-border e-commerce channels.In overseas markets, the e-commerce retail sector in ASEAN is experiencing significant growth, fueled by robust demand for herbal and health-related products in local markets. By adhering to local regulations, Hong Kong pCm enterprises can capitalise on additional business opportunities through online channels.Annual Chinese Medicine Conference to Share Latest Research FindingsTo foster the development of the Chinese medicine industry, the International Conference of the Modernization of Chinese Medicine & Health Products will be held at the Hong Kong Convention and Exhibition Centre from 15 to 16 August 2025. The conference is jointly organised by the Modernized Chinese Medicine International Association, the HKTDC and 10 scientific research institutions. During the event, 21 scholars and experts from medical schools, research institutions, pharmaceutical companies and organisations from mainland China, Hong Kong, Malaysia and Thailand will discuss the latest research progress in the prevention and treatment of tumors, inflammation, and cardiovascular and cerebrovascular diseases using traditional medicine. They will also present a number of related clinical research results and share successful cases. For more details, please visit: https://www.hktdc.com/event/icmcm/en.Report and photo download: https://bit.ly/45kCaXuThe HKTDC today released its research report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry." Pictured from left are Wing Chu, Principal Economist (Greater China Research Team) at the HKTDC, and Prof. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist UniversityWing Chu, Principal Economist (Greater China Research Team) at the HKTDC, pointed out that mainland China has streamlined the approval procedures for eligible traditional proprietary Chinese medicines from Hong Kong and Macao, providing more opportunities for Hong Kong businesses to expand into the Greater Bay Area and mainland marketsProf. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at HKBU, stated that the university’s earlier development of a novel drug for chronic constipation is based on an ancient Chinese herbal formulation and was authorised for clinical research in the United States for the first time. This marked an important step in driving the standardisation and internationalisation of Chinese medicineMedia EnquiriesOgilvy Public RelationsChole ChanTel: (852) 6809 6633Email: chloe.chan@ogilvy.comLeanne PokTel: (852) 9379 9694Email: leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月24日 - (亚太商讯 via SeaPRwire.com) - 日本东京证券交易所挂牌企业 Quantum Solutions Co.,Ltd.（2338.T）于7月23日宣布，正式启动比特币储备业务，计划在未来12个月内逐步建立最多3,000枚比特币（BTC）的储备仓位，作为其长期财务战略中的数字资产配置项目。该计划将由集团全资拥有的香港子公司 GPT Pals Studio Limited 负责执行，初期建设所需的资金已获国际私募投资机构 Integrated Asset Management (Asia) Limited 提供，金额为1,000万美元。这是Quantum Solutions首次在公开层面披露其对加密资产的部署计划。公告显示，该公司将比特币视为未来企业资产结构中的长线"战略型储备品种"， 计划将分阶段实施，以确保其得到适当风险管控和财务管治。3,000枚比特币（BTC）计划将采取阶段化路径实施，购入时机和规模取决于现行市场条件、资本可用性和监管环境。Integrated Asset Management (Asia)是一家总部位于香港的投资公司，于 2014 年主导了对福布斯传媒的收购。该公司由任德章先生创立，专注于公募和私募股权投资。任先生透过其控股公司，包括Integrated Asset Management (Asia) 持有福布斯传媒的多数股权，余下少数股权则由福布斯家族持有。Integrated Asset Management (Asia)参与这项计画突显了机构投资者对将比特币纳入现代企业的财务考量之开放程度日益提高。根据披露，该比特币储备项目将由GPT Pals Studio Limited具体承担相关建设与运维工作，公司已开始建立安全且可审计的数位资产基础设施,包括专属数字资产冷热钱包隔离系统、内部风险控制和会计机制，等基础工作。公司的董事会及审计委员会将根据适用的监管和会计标准，定期监督投资组合的估值、风险敞口和管治。根据当前市场价格测算，3,000枚比特币的总价值约为538亿日元（折合约25亿港元），公司表示，这是一项长期的投资策略，而非短期投机，并表示其资产配置将以财务稳定性与股东价值为导向。Quantum Solutions 执行长（Francis Zhou）表示："我们具备独特优势，可打造以比特币为核心的资本架构。我们的目标不仅是累积比特币，更要以机构级的纪律执行此目标。""我们正与顶尖的资产管理公司、主权财富管理机构以及金融科技领袖进行高层次的磋商，以负责且迅速的方式扩展我们的财务规划蓝图。"当前，全球愈来愈多国际上市企业与大型机构投资者已将比特币纳入财务结构之中，用以对冲通胀及分散货币政策风险。Quantum Solutions 此次计划的推出，正处于该趋势的早期阶段。公司本次选择以香港作为数字资产业务的运营中心，也反映出其对区域金融制度、基础设施与监管环境的信心。Integrated Asset Management Limited创办人任德章表示："Quantum Solutions 展现出明确的策略愿景与坚定的决心。我认为他们在打造具规模的比特币财库方面有潜力引人注目，我期待支持他们在开拓机构通道及资本协调的努力。对于具备- 全球拓展雄心与专注执行力的企业而言，这是一个恰逢其时的良机。"该计划的启动，亦可视为Quantum Solutions从传统科技解决方案企业向多元化财务体系构建方向迈出的关键一步。配合未来业务增长，公司将在资本结构层面持续评估新型资产工具与技术平台的整合可能性，以提升综合财务稳健性与全球应对能力。据悉，若本次比特币储备业务在未来对财务报表构成实质性影响，公司将依据东京交易所相关规定进行必要的信息披露与更新。关于 Quantum SolutionsQuantum Solutions Co.,Ltd.（东京证券交易所：2338.T）是一家总部位于日本东京的高成长科技企业，专注于人工智能、大数据分析及区块链相关技术的研发与应用。公司成立于2004年，并于东京证券交易所挂牌上市。Quantum Solutions 的核心业务涵盖金融科技、医疗健康、智能制造等多个行业领域，致力于以技术驱动产业转型。截至2025年2月28日，公司实现收入约470 万美元，拥有数项游戏类别的注册商标和技术专利。更多信息请访问公司官网：https://www.quantum-s.co.jp/en/corporate前瞻性声明本新闻稿包含根据公司目前可取得之资讯，以及对未来事件与预期所作的若干假设所形成的前瞻性声明。此类声明涉及各种风险与不确定性，包括但不限于政策变动、市场状况、技术发展及监管因素，皆可能导致实际结果与此类声明中所表达或暗示的结果出现重大差异。建议现有及潜在投资者审慎评估潜在风险，并避免对本新闻稿中所包含的任何前瞻性声明寄予过高信赖。此类声明仅适用于本新闻稿发布之日，除法律另有规定外，公司并无义务因新资讯、未来事件或其他情况而更新或修正任何前瞻性声明。如有进一步查询，请联络：香港/国际：Mr. Steven TungEmail: steven.tung@quantum-s.co.jp日本：Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 亚太商讯 via SeaPRwire.com.